Single Fraction Stereotactic Body Radiation Therapy for Breast Cancer

University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, AL
Breast CancerSingle Fraction Stereotactic Body Radiation Therapy - Radiation
Eligibility
18 - 99
All Sexes
What conditions do you have?
Select

Study Summary

This trial offers a new, single-fraction radiation treatment for patients with early stage breast cancer.

Eligible Conditions
  • Breast Cancer

Treatment Effectiveness

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: 0-2 years

0-2 years
Cosmetic outcome post-SBRT
Toxicity levels of 1-3 fractions SBRT for partial breast irradiation assessed by CTCAE v4.0
Toxicity levels of 5 fraction SBRT for partial breast irradiation assessed by CTCAE v4.0
Toxicity levels of single fraction SBRT for partial breast irradiation assessed by CTCAE v4.0
Toxicity of breast SBRT using CTCAE v4.0

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

5 Fraction Breast Stereotactic Body Radiation Therapy
1 of 3
1-3 Fraction Breast Stereotactic Body Radiation Therapy
1 of 3
Single Fraction Breast Stereotactic Body Radiation Therapy
1 of 3

Experimental Treatment

40 Total Participants · 3 Treatment Groups

Primary Treatment: Single Fraction Stereotactic Body Radiation Therapy · No Placebo Group · N/A

5 Fraction Breast Stereotactic Body Radiation Therapy
Radiation
Experimental Group · 1 Intervention: 5 Fraction Stereotactic Body Radiation Therapy · Intervention Types: Radiation
1-3 Fraction Breast Stereotactic Body Radiation Therapy
Radiation
Experimental Group · 1 Intervention: 1-3 Fraction Stereotactic Body Radiation Therapy · Intervention Types: Radiation
Single Fraction Breast Stereotactic Body Radiation Therapy
Radiation
Experimental Group · 1 Intervention: Single Fraction Stereotactic Body Radiation Therapy · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 0-2 years

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,472 Previous Clinical Trials
2,246,029 Total Patients Enrolled
27 Trials studying Breast Cancer
4,286 Patients Enrolled for Breast Cancer
D. Hunter Boggs, MDPrincipal InvestigatorUniversity of Alabama at Birmingham

Eligibility Criteria

Age 18 - 99 · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many participants can be accepted into this research endeavor?

"Affirmative, the data on clinicaltrials.gov indicates this trial is actively searching for participants and was posted on August 20th 2019 with a last update of November 7th 2022. The study requires 40 individuals who will be recruited from 1 medical institution." - Anonymous Online Contributor

Unverified Answer

Do I meet the requirements to partake in this research?

"This research is recruiting 40 individuals affected by [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) who are aged 18-99. Participants must meet the following criteria: biopsy confirmed invasive mammary carcinoma, ductal carcinoma in situ (DCIS) of the breast; medullary, papillary, mucinous (colloid), and tubular histologies allowed; over 50 years old; maximal pathologic tumor size less than 2.0 cm for invasive tumours or less than 2.5 cm for pure DCIS cases; estrogen receptor positivity (>10%); be eligible for conservative therapy with lumpectomy exhibiting a minimum margin width of two millimetres; clinically" - Anonymous Online Contributor

Unverified Answer

Is the age prerequisite for this clinical trial restricted to those over 20 years old?

"In order to participate in this clinical study, individuals must be aged 18-99. There are also 74 trials for minors and 2507 studies targeting those over the age of 65." - Anonymous Online Contributor

Unverified Answer

Is the enrollment period for this research still in progress?

"As indicated on clinicaltrials.gov, this trial is in the process of recruiting participants and was first posted on August 20th 2019 with its most recent revision made on November 7th 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.